A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
Recruiting now · Phase 2
Conditions studied: Diabetic Foot Ulcer
In brief
The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.
Key facts
- Study ID
- NCT06852976
- Run by
- Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
- People needed
- 60
- Starts
- 2025-03-12
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2025-03-07
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Willing and able to participate and comply with all trial requirements and able to provide signed and dated informed consent prior to initiation of any trial procedures;
- Male or female 18-75 years;
- Meet diagnostic criteria for a diabetic ulcer with the presence of at least one target ulcer that meets the characteristics:
- Located on dorsal or plantar surface of foot or below the knee.
- Wagner grade 2, ulcerated lesion at or below the knee, without systemic infection.
- The target ulcer should be the largest, and all each individual ulcers size should be less than 25cm2. All ulcers will be treated the same as the target ulcer.
- Target ulcers persisted for at least 12 weeks prior to enrollment and have been on standard of care for at least 4 weeks prior to enrollment.
- There is a minimum 3cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot (post-debridement).
You may not qualify if…
- Allergy to the main components or excipients of MDI-1228_mesylate gel, allergy to JAK inhibitors (tofacitib, baricitinib, ruxolitinib), or individuals with allergic constitution.
- Skin ulcers or chronic wounds caused by electroshock, chemicals, radioactive material etc.
- The target ulcer has reduced in size by ≥30% in the last 4 weeks under standard treatment.
- Those with cancerous ulcers or connective tissue diseases including lupus erythematosus, rheumatoid arthritis, scleroderma, etc.
Where it is running
- Site 001 — Durham, North Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.